Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- CRS Neurotoxicity after CAR T-Cell
CRS Neurotoxicity after CAR T-Cell
Cytokine release syndrome (CRS) and neurotoxicity after CAR T-cell therapy are serious treatment-related adverse events. Both CRS and neurotoxicity are potentially life threatening.
I’m writing about these two side effects of CAR-T cell therapy because in my experience as a MM survivor, I’ve learned that oncologists, as capable as they can be, often don’t do a good job of explaining possible side effects of aggressive therapies such as an ASCT or CAR-T cell therapy.
I believe that MM patients can take steps to prepare themselves to reduce the risk of side effects.
What is cytokine release syndrome?
CAR-T and neurotoxicity: frequency and management
According to the article linked below, virtually all patients undergoing CAR-T therapy will experience either/0r/both neurotoxicity and CRS. I would rather know than not know.
Email me at David.PeopleBeatingCancer@gmail.com with questions about MM and possible side effects.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell Therapy
“While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response.
The most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
“The spectrum of symptoms [for CRS] runs from mild to severe,” said Bilal Siddiqui, MD, of the University of Texas MD Anderson Cancer Center in Houston. “The mild cases manifest as fever and flu-like symptoms, but they can become more severe. They can involve the lungs, they can cause a drop in blood pressure, and in the most severe cases, blood pressure can get so low that patients actually have to go into the intensive care unit to get really aggressive treatment.”
“CRS is usually reversible and we use medicines to switch off the immune system, the most common being corticosteroids and targeted medications like tocilizumab (Actemra) — these are really the workhorses of how we reverse CRS,” he added.
Tocilizumab — an interleukin (IL)-6 receptor inhibitor — was approved by the FDA opens in a new tab or window in 2017 for the treatment of severe or life‐threatening CAR T cell‐induced CRS in patients ages 2 years and older, and is now widely used to manage CRS associated with CAR T-cell therapy.
Like CRS, ICANS symptoms can range from mild to severe, with mild cases manifesting as confusion or tremor, Siddiqui said. “But, it can become severe and lead to seizures, nonresponsiveness, swelling in the brain, [and] coma, and so this is something that we take very, very seriously and treat seriously and aggressively.”
According to guidelines from the American Society of Clinical Oncologyopens in a new tab or window, the mainstay of ICANS treatment is supportive care and corticosteroids. Tocilizumab will not resolve it and may, in fact, worsen it. Thus, the management of ICANS may take priority over low-grade CRS in cases where these toxicities occur simultaneously.
“The two toxicities tend to happen very quickly with immunotherapy — often within hours of the initial infusion, so that for the most part, patients do need to be monitored in the hospital so that we can catch these side effects early and jump on them,” Siddiqui said.
The incidence of CRS has been reported to range from 57% to 93% and ICANS from 20% to 70% The frequency and severity of these toxicities can vary depending on which CAR T-cell therapy is being used, which disease is being treated, and even among patients who have the same disease and same CAR T-cell product, said Michael Jain, MD, PhD, of the Moffitt Cancer Center in Tampa, Florida.
As to which patients are more susceptible to CRS or ICANS, “one of the biggest determinants of the likelihood of getting these toxicities is often related to the tumor burden that the patient has,” he added…
Jain said that co-stimulation is also a key factor in activating T cells, and products that use CD28 for co-stimulation are likely to produce more CRS and neurotoxicity than products that use 4-1BB.
“There are things we do as physicians that can also influence the likelihood of getting these toxicities, such as giving steroids or anti-cytokine drugs as prophylaxis, or intervening earlier for lower-grade toxicities,” he said. “While we’ve gotten better at preventing these toxicities — I would say for most products the likelihood of getting grade 3 or higher CRS is generally less than 10% and can get a lot lower for some products — sometimes, despite our best efforts, patients will get severe versions of these toxicities.”
Emerging Treatments
Jain pointed out that the IL-1 receptor antagonist anakinra (Kineret) has emerged as a common agent used after tocilizumab and/or with corticosteroids, and is being evaluated in a number of prospective trials for the prevention and treatment of CRS and/or ICANS.
In a retrospective study of 43 patients with B-cell or plasma cell malignancies, researchers found that treatment with anakinra appeared to be feasible and safe for refractory CRS or ICANS after CAR T-cell therapy, and that a higher dose may lead to faster resolution and was independently associated with lower treatment-related mortality. Moreover, they observed an overall response rate of 77% after CAR T-cell therapy in these patients, suggesting anakinra had a limited effect on its efficacy.
(CRS) and neurotoxicity after CAR T-cell (CRS) and neurotoxicity after CAR T-cell (CRS) and neurotoxicity after CAR T-cell